Rafferty Joins Team of Attorneys Leading Actos Bladder Cancer Litigation

 

U.S. District Judge Rebecca Doherty of Louisiana has selected Troy Rafferty of Levin, Papantonio, Thomas, Mitchell, Rafferty & Proctor as one of the lead attorneys in the twelve-member plaintiffs’ steering committee for the class action product liability litigation against Actos.

Rafferty has been the recipient of numerous distinctions including selection as one of the Top 100 Trial Lawyers by the American Trial Lawyers Association. He has also handled some of the nation’s largest pharmaceutical and mass tort cases.

Actos is a prescription medication used for the treatment of type 2 diabetes that was approved by the Food and Drug Administration in 1999. However, the drug has since been linked to an increased risk for bladder cancer.

In December 2011, the United States Judicial Panel on Multidistrict Litigation transferred 11 civil actions against Actos to the United States District Court for the Western District of Louisiana for coordinated or consolidated pretrial proceedings. Since that time, additional plaintiffs have come forward, alleging that known dangers from Actos were intentionally hidden by the product manufacturer, Takeda Pharmaceuticals America Inc.

If you believe you developed bladder cancer related to your Actos prescription, please contact PersonalInjury.com for a free case evaluation and to locate an experienced pharmaceutical injury attorney near you.